Karyopharm Therapeutics (KPTI)

• Karyopharm Therapeutics Inc. announced preliminary unaudited Full Year 2025 total revenue of approximately $145 million and U.S. XPOVIO net product revenue of approximately $115 million.
• For the fourth quarter of 2025, preliminary unaudited total revenue is expected to be approximately $33 million and U.S. XPOVIO net product revenue approximately $32 million.
• As of December 31, 2025, cash, cash equivalents, restricted cash, and investments were approximately $64 million, with existing liquidity expected to fund operations into the second quarter of 2026.
• The company anticipates top-line data from the Phase 3 SENTRY trial in myelofibrosis in March 2026 and from the Phase 3 XPORT-EC-042 trial in endometrial cancer in mid-2026.

• Karyopharm Therapeutics announced its preliminary unaudited financial results for full year and fourth quarter 2025, with key revenue figures detailed below.
• The company anticipates top-line data from the Phase 3 SENTRY trial in myelofibrosis in March 2026 and top-line data from the Phase 3 XPORT-EC-042 trial in endometrial cancer in mid-2026. These are expected to be significant catalysts for the company.
• As of December 31, 2025, cash, cash equivalents, restricted cash, and investments were approximately $64 million, with existing liquidity expected to fund operations into the second quarter of 2026.

Quantitative Information:

• Karyopharm (KPTI) anticipates Phase III SENTRY trial results for Selinexor plus Ruxolitinib in myelofibrosis in March.
• The company estimates the myelofibrosis opportunity to be up to a $1 billion peak revenue opportunity in the U.S. alone.
• Early Phase I data for Selinexor plus Ruxolitinib demonstrated a 79% SVR35 at week 24 and an 18.5 improvement in absolute TSS relative to baseline, significantly higher than historical ruxolitinib rates.
• A recent refinancing package provided Karyopharm with $78 million in cash, extending its cash runway into Q2 2026.
• Karyopharm has an established commercial organization with 80% overlap with myelofibrosis prescribers and market research indicates a 75% intent to prescribe among physicians for the combination therapy.

• Karyopharm Therapeutics (KPTI) is anticipating Phase III SENTRY trial results in March for its lead compound, selinexor, in combination with ruxolitinib for frontline myelofibrosis.
• The SENTRY trial's co-primary endpoints are SVR35 (spleen volume reduction of 35% or more) and absolute Total Symptom Score (TSS), both powered for success, with Phase I data showing 79% SVR35 for the combination compared to 30-35% for ruxolitinib alone.
• The company projects a $1 billion peak revenue opportunity in the U.S. for this myelofibrosis indication, leveraging an existing commercial organization and a manageable safety profile.
• A recent refinancing package has extended Karyopharm's cash runway into Q2 2026, beyond the anticipated myelofibrosis readout.

• Karyopharm Therapeutics is a commercial-stage oncology company focused on areas of high unmet need, with its lead compound, XPOVIO (selinexor), commercialized in multiple myeloma.
• The company is awaiting Phase III SENTRY trial results for selinexor plus ruxolitinib in myelofibrosis, with data anticipated in March.
• Phase I data for the combination demonstrated strong efficacy, with 79% of patients achieving SVR35 at week 24 and an 18.5-point improvement in absolute TSS relative to baseline, significantly exceeding historical ruxolitinib alone.
• Karyopharm estimates a U.S. peak revenue opportunity of up to $1 billion for this combination, with physicians indicating a 75% intent to prescribe based on the profile.
• A recent refinancing package provided approximately $78 million in cash, extending the company's cash runway into Q2 2026.

• Karyopharm reported Q3 revenues of approximately $32 million for XPOVIO (selinexor) and guided for $110-$120 million in full-year revenue.
• The company anticipates a Phase 3 SENTRY trial readout for selinexor in myelofibrosis in March 2026, with prior Phase 1 data showing a 79% SVR35 rate in frontline patients.
• Data from the Phase 3 XPORT-EC-042 trial for selinexor in endometrial cancer is expected in mid-2026.
• A multi-part financial restructuring in October provided Karyopharm with a cash runway into Q2 2026.

• Karyopharm reported Q3 revenues of approximately $32 million and guided for $110 million-$120 million for the full year.
• The company expects pivotal data readouts for selinexor in myelofibrosis in March 2026 and in endometrial cancer in mid-2026.
• The myelofibrosis opportunity, with a Phase I SENTRY trial showing a 79% SVR35 rate for selinexor plus ruxolitinib, is estimated to be a $1 billion peak revenue opportunity in the U.S..
• A recent financial restructuring in October established $231 million in debt and extended Karyopharm's cash runway into Q2 2026.

• Karyopharm reported Q3 2025 total revenue of $44 million, a 13% increase year-over-year, with U.S. XPOVIO net product revenue growing 8.5% to $32 million. The company posted a net loss of $33.1 million, or $3.82 per share.
• The company completed enrollment in its Phase 3 SENTRY trial for frontline myofibrosis, with top-line results anticipated in March 2026.
• Karyopharm strengthened its financial position, securing approximately $100 million in additional capital and extending its cash runway into Q2 2026.
• Full-year 2025 guidance was updated, with total revenue expected between $140-$155 million and US XPOVIO net product revenue between $110-$120 million, while R&D and SG&A expenses were lowered to $235-$245 million.

• KPTI reported Q3 2025 total revenue of $44.0 million, with XPOVIO net product revenue at $32.0 million, marking an 8.5% increase from Q3 2024. The company recorded a net loss of $(33.1) million for the quarter.
• The company reaffirmed its full-year 2025 total revenue guidance of $140-$155 million and U.S. XPOVIO net product revenue guidance of $110-$120 million.
• KPTI's existing liquidity is projected to fund planned operations into the second quarter of 2026.
• Top-line data from the Phase 3 SENTRY trial in Myelofibrosis is expected in March 2026, and from the Phase 3 trial in Endometrial Cancer in mid-2026.
• The Selinexor plus Ruxolitinib combination in Myelofibrosis is estimated to have a peak annual net sales potential of up to ~$1 billion in the U.S. market.

• Karyopharm Therapeutics Inc. reported total revenue of $44.0 million for the third quarter of 2025, an increase from $38.8 million in the third quarter of 2024, with U.S. XPOVIO net product revenue reaching $32.0 million. The company reported a net loss of $33.1 million, or $3.82 per basic and diluted share, for the third quarter of 2025.
• The company reaffirmed its full-year 2025 total revenue guidance of $140 million to $155 million and U.S. XPOVIO net product revenue guidance of $110 million to $120 million. Additionally, the range for R&D and selling, general and administrative (SG&A) expenses was lowered to $235 million to $245 million.
• Enrollment for the Phase 3 SENTRY trial in myelofibrosis was completed in early September 2025, with top-line data anticipated in March 2026. Top-line data for the Phase 3 XPORT-MM-031 trial in multiple myeloma is expected in the first half of 2026, and for the Phase 3 XPORT-EC-042 trial in endometrial cancer in mid-2026.
• Karyopharm expects its existing liquidity to be sufficient to fund planned operations into the second quarter of 2026.